Literature DB >> 11369016

Effect of intensive lipid-lowering strategy on low-density lipoprotein particle size in patients with type 2 diabetes mellitus.

S D Niemeijer-Kanters1, G M Dallinga-Thie, F C de Ruijter-Heijstek, A Algra, D W Erkelens, J D Banga, H Jansen.   

Abstract

A preponderance of small dense LDL particles is strongly associated with the occurrence of atherosclerotic disease. Although several studies have documented an increased prevalence of small dense LDL particles in diabetes mellitus no data are available to show the effect of lipid-lowering treatment upon the improvement of LDL particle size. In the present study we examined the effect of lipid-lowering treatment, following an intensive lipid-lowering strategy for 30 weeks pursuing ADA recommended target lipid levels, on LDL particle size in 50 type 2 diabetic patients with moderate hyperlipidemia. At week 0, 24 patients (48%) were characterized by small dense LDL phenotype pattern B. After the treatment period a shift towards normal LDL particle size was observed in 17 patients but seven patients (29%) showed the more atherogenic LDL subclass pattern B. After treatment, plasma HDL-cholesterol was significantly lower (P<0.05) in these patients compared to those who had LDL subclass pattern A. Multivariate regression analysis revealed VLDL-cholesterol or triglycerides and HDL(3)-cholesterol as independent determinants for LDL particle size. Change in HDL(2)-cholesterol was an independent determinant for change in LDL particle size. In conclusion, a strategy of intensive lipid-lowering, with the intention to reduce triglyceride levels below 1.7 mmol/l, may be insufficient to ensure improvement in LDL size in all patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11369016     DOI: 10.1016/s0021-9150(00)00642-0

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  5 in total

1.  Impact of LDL apheresis on atheroprotective reverse cholesterol transport pathway in familial hypercholesterolemia.

Authors:  Alexina Orsoni; Elise F Villard; Eric Bruckert; Paul Robillard; Alain Carrie; Dominique Bonnefont-Rousselot; M John Chapman; Geesje M Dallinga-Thie; Wilfried Le Goff; Maryse Guerin
Journal:  J Lipid Res       Date:  2012-02-15       Impact factor: 5.922

Review 2.  Dietary fats and diabetes mellitus: is there a good fat?

Authors:  C J Segal-Isaacson; E Carello; J Wylie-Rosett
Journal:  Curr Diab Rep       Date:  2001-10       Impact factor: 4.810

3.  Altered relationship of plasma triglycerides to HDL cholesterol in patients with HIV/HAART-associated dyslipidemia: further evidence for a unique form of metabolic syndrome in HIV patients.

Authors:  Catherine N Vu; Raul Ruiz-Esponda; Eric Yang; Evelyn Chang; Baiba Gillard; Henry J Pownall; Ron C Hoogeveen; Ivonne Coraza; Ashok Balasubramanyam
Journal:  Metabolism       Date:  2013-03-19       Impact factor: 8.694

4.  Hepatic triglyceride content does not affect circulating CETP: lessons from a liraglutide intervention trial and a population-based cohort.

Authors:  Huub J van Eyk; Lisanne L Blauw; Maurice B Bizino; Yanan Wang; Ko Willems van Dijk; Renée de Mutsert; Johannes W A Smit; Hildo J Lamb; Ingrid M Jazet; Patrick C N Rensen
Journal:  Sci Rep       Date:  2019-07-10       Impact factor: 4.379

5.  High-density lipoprotein (HDL) particle subpopulations in heterozygous cholesteryl ester transfer protein (CETP) deficiency: maintenance of antioxidative activity.

Authors:  Sandrine Chantepie; Andrea E Bochem; M John Chapman; G Kees Hovingh; Anatol Kontush
Journal:  PLoS One       Date:  2012-11-26       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.